Pure Global

Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus - Trial NCT06297408

Access comprehensive clinical trial information for NCT06297408 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Ming Ju Biotechnology Co., Ltd. and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06297408
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06297408
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus
Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus Single Arm Phase I and Phase II Randomized Controlled Open, Multicenter Study

Study Focus

Relma-cel

Interventional

drug

Sponsor & Location

Shanghai Ming Ju Biotechnology Co., Ltd.

Timeline & Enrollment

Phase 1

Mar 01, 2024

May 01, 2026

24 participants

Primary Outcome

DLT rate,determine RP2D

Summary

To assess the safety tolerability pharmacokinetics and pharmacodynamics of Relma-cel in
 moderate or severe active systemic lupus erythematosus (SLE) subjects in China.

ICD-10 Classifications

Systemic lupus erythematosus
Systemic lupus erythematosus, unspecified
Lupus erythematosus
Systemic lupus erythematosus with organ or system involvement
Other forms of systemic lupus erythematosus

Data Source

ClinicalTrials.gov

NCT06297408

Non-Device Trial